Form 4 for EW Edwards Lifesciences
Accepted 2024-05-06 00:00:00 ET · period of report 2024-05-03 · accession 0001225208-24-005706 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-05-06 | 2024-05-03+ | EW | Szyman Catherine M. | CVP, Critical Care | F - Tax | $85.23 | -3,921 | 43.2K | -8% | -$334.2K |
| D | 2024-05-06 | 2024-05-04 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $0.00 | +5,796 | 49.0K | +13% | $0 |
| D | 2024-05-06 | 2024-05-04 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $0.00 | -5,796 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-04 | F | D | 3,442 | $85.25 | 45,576.44 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-04 | M | A | 5,796 | $0.00 | 49,018.44 | D | — | — | (F1) On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. |
| 3 | Common | Common Stock | 2024-05-03 | F | D | 479 | $85.06 | 43,222.44 | D | — | — | |
| 4 | Derivative | Performance Rights | 2024-05-04 | M | D | 5,796 | $0.00 | 0 | D | — · 2024-05-04 to 2028-05-03 | 5,796 Common Stock | (F1) On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. |